Investors in Mouwasat Medical Services Company (TADAWUL:4002) had a good week, as its shares rose 2.1% to close at ر.س63.50 following the release of its second-quarter results. Mouwasat Medical Services reported in line with analyst predictions, delivering revenues of ر.س876m and statutory earnings per share of ر.س4.11, suggesting the business is executing well and in line with its plan. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Taking into account the latest results, the consensus forecast from Mouwasat Medical Services' nine analysts is for revenues of ر.س3.62b in 2026. This reflects a satisfactory 7.4% improvement in revenue compared to the last 12 months. Statutory per-share earnings are expected to be ر.س4.20, roughly flat on the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of ر.س3.62b and earnings per share (EPS) of ر.س4.32 in 2026. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.

The consensus price target held steady at ر.س84.67, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Mouwasat Medical Services at ر.س118 per share, while the most bearish prices it at ر.س63.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's clear from the latest estimates that Mouwasat Medical Services' rate of growth is expected to accelerate meaningfully, with the forecast 15% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 9.9% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 11% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Mouwasat Medical Services is expected to grow much faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at ر.س84.67, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Mouwasat Medical Services analysts - going out to 2028, and you can see them free on our platform here.

You can also view our analysis of Mouwasat Medical Services' balance sheet, and whether we think Mouwasat Medical Services is carrying too much debt, for free on our platform here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.